Cookson Peirce & Co. Inc. Sells 484,123 Shares of Sanofi (NASDAQ:SNY)

Cookson Peirce & Co. Inc. decreased its position in shares of Sanofi (NASDAQ:SNY) by 96.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,235 shares of the company’s stock after selling 484,123 shares during the quarter. Cookson Peirce & Co. Inc.’s holdings in Sanofi were worth $758,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SNY. BlackRock Inc. increased its stake in shares of Sanofi by 2.5% in the 1st quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock valued at $546,804,000 after acquiring an additional 249,619 shares in the last quarter. Morgan Stanley increased its stake in shares of Sanofi by 19.3% in the 4th quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock valued at $374,513,000 after acquiring an additional 1,251,199 shares in the last quarter. Invesco Ltd. increased its stake in shares of Sanofi by 2.3% in the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock valued at $260,697,000 after acquiring an additional 112,404 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Sanofi by 276.1% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock valued at $172,611,000 after acquiring an additional 2,468,271 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in shares of Sanofi by 0.8% in the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company’s stock valued at $170,536,000 after acquiring an additional 25,457 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price target for the company. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Price Performance

SNY opened at $45.80 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The company has a market capitalization of $115.86 billion, a price-to-earnings ratio of 19.41, a P/E/G ratio of 1.73 and a beta of 0.61. The firm’s fifty day moving average price is $47.56 and its two-hundred day moving average price is $48.71. Sanofi has a 1 year low of $42.63 and a 1 year high of $57.82.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. As a group, analysts anticipate that Sanofi will post 4.16 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s payout ratio is currently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.